Prostate cancer treatment could be “supercharged” by a new way of weakening malignant cells, say scientists.
A new “vulnerability” in prostate cancer cells that could improve treatment for the second most common cancer in men worldwide (second only to skin cancer) was discovered by an international team of researchers.
They found that two enzymes – PDIA1 and PDIA5 – play a crucial role in helping prostate cancer cells to grow, survive, and resist treatment.
Although treatments such as hormone therapy and AR-targeting drugs have helped many prostate cancer patients, resistance to the therapies is a major challenge.
The new discovery could help overcome that hurdle and improve the survival chances of men with advanced prostate cancer, say scientists.
Scientists believe that a novel method of weakening cancerous cells could “supercharge” the treatment of prostate cancer.
Researchers from around the world have found a new “vulnerability” in prostate cancer cells that may help treat the second most common cancer in men globally, after skin cancer.
They discovered that two enzymes, PDIA1 and PDIA5, are essential for the growth, survival, and resistance to treatment of prostate cancer cells. They defend the androgen receptor (AR), a protein that feeds cancer, by acting as “molecular bodyguards.”.
The AR becomes unstable and disintegrates when PDIA1 and PDIA5 are blocked, which causes the cancer cells to die and the tumor to shrink in both lab-grown cells and animal models.
The effectiveness of the treatment was also found to be greatly increased by the researchers when enzalutamide, a commonly used medication for prostate cancer, was combined with medications that block PDIA1 and PDIA5.
“This is an exciting step forward,” the study’s lead author, Professor Jianling Xie, stated.
Resistance to the treatments is a significant problem, despite the fact that many patients with prostate cancer have benefited from treatments like hormone therapy and medications that target the AR receptor. According to scientists, the new finding may help get past that obstacle and increase the chances that men with advanced prostate cancer will survive.
MORE BREAKTHROUGHS: Researchers Find a Basic Supplement That Makes Prostate Cancer Cells Destruct.
The study’s senior author, Professor Luke Selth of Flinders University in Australia, stated, “We’ve found a hitherto unidentified mechanism that prostate cancer cells use to protect the androgen receptor, which is a key driver of the disease.”.
By focusing on these enzymes, we can weaken the AR and increase the tumors’ susceptibility to current treatments like enzalutamide. “”.
Dr. According to Xie, who initiated the study while attending Flinders University, the combination therapy demonstrated “strong potential” for further clinical trials by performing well in mice and patient-derived tumor samples.
According to our research, PDIA1 and PDIA5 not only aid in the growth of cancer but also show promise as targets for novel therapies that may complement current medications. “.”.
The study, which was published last week in the Proceedings of the National Academy of Sciences (PNAS) journal, also discovered that PDIA1 and PDIA5 aid cancer cells in managing stress and sustaining energy production. Blocking them damages the mitochondria, which are the parts of the cell that produce energy, and results in oxidative stress, which weakens the cancer even more.
According to Xie, it’s similar to turning off the engine and the fuel simultaneously.
These enzymes are particularly appealing targets because they have the dual effect of affecting the AR and the cancer’s energy source. “”.
LEAD MORE: Cedars-Sinai Phase III Clinical Trial Shows “Promise” in New Approach to Treating Aggressive Prostate Cancer.
Professor… Selth issued a warning, saying that more work is required to ensure that treatments are both safe and effective for patients.
